Dementia Medications in Canada: Costs and Coverage

Understanding Dementia Medications in Canada

Approximately 600,000 Canadians live with dementia, and that number is projected to nearly double by 2030. While no medication cures dementia, several can slow cognitive decline and manage symptoms. Understanding the costs and coverage landscape is essential for families navigating this difficult diagnosis.

Currently Available Medications

Cholinesterase Inhibitors

These are the most commonly prescribed first-line treatments for mild to moderate Alzheimer's disease:

Medication	Brand Name	Generic Available	Brand Cost/Month	Generic Cost/Month
Donepezil	Aricept	Yes	$180–$220	$25–$45
Rivastigmine (oral)	Exelon	Yes	$190–$240	$35–$55
Rivastigmine (patch)	Exelon Patch	Yes	$210–$260	$80–$120
Galantamine	Reminyl	Yes	$170–$210	$30–$50

Generic donepezil is the most cost-effective option at $25–$45 per month and is covered by every provincial drug plan in Canada.

NMDA Receptor Antagonist

Memantine (Ebixa) is prescribed for moderate to severe Alzheimer's and is often used in combination with a cholinesterase inhibitor.

Brand cost: $160–$200/month
Generic cost: $30–$55/month
Coverage: Listed on most provincial formularies, though some require Special Authorization

Combination Therapy

Using donepezil and memantine together is common. The monthly cost ranges from $55–$100 for generics or $340–$420 for brand names.

Newer Treatments

Lecanemab (Leqembi)

Lecanemab is an anti-amyloid antibody approved by Health Canada in 2024 for early Alzheimer's disease. It represents a new class of disease-modifying therapies.

Estimated cost: $26,000–$35,000 per year
Administration: IV infusion every two weeks
Provincial coverage: Under review; not yet listed on most provincial formularies
Private insurance: Coverage varies; many plans are evaluating

Aducanumab (Aduhelm)

Not approved in Canada. Health Canada has not granted market authorization for this controversial medication.

Provincial Coverage Breakdown

Province	Donepezil (Generic)	Memantine (Generic)	Special Authorization Needed?
Ontario (ODB)	Covered	Covered	No (donepezil), Yes (memantine)
British Columbia	Covered	Covered	Yes (both)
Alberta	Covered	Covered	No
Quebec (RAMQ)	Covered	Covered	Yes (memantine)
Saskatchewan	Covered	Covered	Yes (both)
Manitoba	Covered	Covered	Yes (memantine)

Special Authorization means your doctor must submit clinical documentation proving the medication is medically necessary. Approval rates for dementia drugs are generally high (75–85%) when criteria are met.

Managing Behavioural Symptoms

Dementia often involves behavioural and psychological symptoms (BPSD) such as agitation, aggression, sleep disturbances, and psychosis. Medications sometimes used include:

Risperidone (Risperdal): $15–$30/month generic — the only antipsychotic with a Health Canada indication for dementia-related aggression
Trazodone: $8–$15/month generic — commonly used off-label for sleep disturbances
Citalopram: $6–$12/month generic — sometimes used for agitation

Important: Antipsychotic medications carry a black box warning for increased mortality in elderly dementia patients. They should be used only when non-drug approaches have failed and at the lowest effective dose.

Practical Cost-Saving Strategies

Always request generics. Switching from brand Aricept to generic donepezil saves over $1,800 per year.

Apply for Special Authorization early. Do not wait until your provincial coverage lapses.

Check for compassionate access programs. Some manufacturers offer patient assistance programs for newer drugs.

Use TransparentMedz to compare prices. Pharmacy markups on dementia drugs vary significantly.

Explore Veterans Affairs coverage if the patient is a veteran — VAC has a broader formulary.

Caregiver Supports

Beyond medication, check if your province offers:

Respite care funding for caregivers
Home care support including medication management
Alzheimer Society programs (free in every province)

The Bottom Line

Generic donepezil remains the most cost-effective first-line treatment for Alzheimer's, costing as little as $25/month with provincial coverage. For families facing dementia, the key is starting treatment early, using generics, applying for Special Authorization where needed, and comparing prices on TransparentMedz to minimize out-of-pocket costs.